Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Serotonergic targets in depression.

Derek N Middlemiss¹, Gary W Price, Jeannette M Watson

¹Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Third Avenue, Harlow, Essex CM19 5AW, UK.

Current Opinion in Pharmacology

|January 12, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.

Virology journal·2015

Same author

A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.

Vaccine·2014

Same author

Distinct muscarinic acetylcholine receptor subtypes mediate pre- and postsynaptic effects in rat neocortex.

BMC neuroscience·2012

Same author

Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia.

Molecular pharmacology·2011

Same author

The muscarinic M(4) receptor is the functionally predominant subtype in rat and mouse striatum as demonstrated using [(35)S] GTPγS binding.

European journal of pharmacology·2010

Same author

The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists.

Bioorganic & medicinal chemistry letters·2010

Selective serotonin reuptake inhibitors effectively treat depression, supporting the role of serotonin (5-hydroxytryptamine or 5-HT) in mood disorders. Further research explores other serotonin targets and combination therapies for depression.

Area of Science:

Neuroscience
Pharmacology
Psychiatry

Background:

Selective serotonin reuptake inhibitors (SSRIs) are effective depression treatments.
SSRIs support the hypothesis of impaired 5-hydroxytryptamine (5-HT) neurotransmission in depression.
Research is exploring additional 5-HT targets for depression.

Purpose of the Study:

To investigate the role of various 5-HT receptor subtypes in depression.
To evaluate combination treatments involving SSRIs and 5-HT(1A) receptor ligands.

Main Methods:

Review of existing research on 5-HT neurotransmission and depression.
Analysis of clinical studies on combination therapies.

Main Results:

Related Experiment Videos

SSRIs confirm the link between serotonin and depression.

Clinical trials are investigating combined SSRI and 5-HT(1A) ligand treatments.

Conclusions:

Impaired 5-HT neurotransmission is a key factor in depression.
The role of other 5-HT receptor subtypes in depression requires further investigation.